Going to be dropping several ASCO 2025 analyses as the conference continues on. This is my first of the series on Summit’s HARMONi readout and how based on what your biases are you are either going to think that data was very encouraging or very disappointing for the PD-(L)1xVEGF bispecific antibody class. The classic “Is it a Rabbit or a Duck” optical illusion.